Supreme Court Explains that Comprehensive Motor Insurance Covers Occupants of a Vehicle  ||  Supreme Court: Judgments Operate Retrospectively Unless Made Prospective  ||  Supreme Court Clarifies Principles Governing Witness Recall under Order 18 Rule 17 of CPC  ||  Gujarat High Court: Res Judicata Prevents Trustees from Reopening Trust Property Disputes  ||  Allahabad HC: Trial Courts Cannot Examine Witnesses to Generate Fresh Evidence Before Cognizance  ||  Rajasthan HC: Funds Collected From an Illegal Toll Plaza Must Be Used For Tree Plantation  ||  Delhi HC: Minor’s Signature Alone Cannot Establish Consent for Pregnancy Termination  ||  Karnataka HC Allows ECIR Challenge under Article 226, Rejects ED’s Immunity Claim  ||  Allahabad High Court Upholds Transfer of a Dissolved Society's Assets to its Successor Company  ||  P&H HC: Cheque Bounce Cases Remain Compoundable Even After Appellate Courts Uphold Conviction    

Glenmark Settles Patent Litigation over Milnacipran Hydrochloride Tablets - (22 Dec 2015)

Glenmark Pharmaceuticals Inc., USA have entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, and Royalty Pharma Collection Trust to settle and dismissed outstanding patent litigation related to Glenmark's Abbreviated New Drug Application.

Tags : GLENMARK PHARMACEUTICALS INC   FOREST LABORATORIES   LLC   FOREST LABORATORIES HOLDINGS     ROYALTY PHARMA COLLECTION TRUST  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved